The Future of DDR-Targeted Oncology
The 9th DDR Inhibitors Summit returns to Boston in 2026, uniting experts from biopharma, biotech, and academia to drive the next generation of DNA Damage Response (DDR)-targeted therapies.
This event is a must-attend for those pushing the boundaries of synthetic lethality and precision oncology, with a focus on novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK.
- Biomarker-driven discovery
- Combination strategies
- Resistance-mitigation approaches
Hear exclusive updates from leaders and innovators across the DDR field, including representatives from Artios Pharma, AstraZeneca, Merck, Eli Lilly, IDEAYA Biosciences, Repare Therapeutics, and more.
Author's summary: DDR Inhibitors Summit drives cancer therapy innovation.
More News
- Employees are receiving renewed furlough notices as shutdown enters second month, this time without back pay guarantees
- Bose headphones and earbuds return to all-time lows for Black Friday
- No Giannis, No Problem — Bucks Take Down Warriors as Antetokounmpo Steals the Show in Minion Costume
- The unexpected reaction of Tyreek Hill after the firing of Dolphins general manager Chris Grier
- Sinners: blood, blues and vampires - The Stute
- For they will chart: The Pretty Reckless returns to #1 on ’Billboard’ Mainstream Rock Airplay – 105.7 The Point
- JD Vance pushes back on comments about his interfaith marriage with wife
- Amazon’s newest streaming stick is missing a Spotify app.
- Donal Skehan takes cheeky dig at Eurosong controversy with perfect Halloween costume
- Why Ryan Rollins loved Draymond Green coming for him after Stephen Curry incident